Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic Applied BioSolutions (Nasdaq: DYAI) announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program targeting advanced cellulose processing. The initiative builds on the commercialization of EN3ZYME™ and further showcases the scalability and repeatability of Dyadic’s Dapibus™ microbial expression platform.
The newly developed enzyme is intended for applications including pulp biorefining, microcrystalline cellulose and nanocellulose production. According to Dyadic, the program addresses a multi-billion-dollar industrial enzyme market and supports a dual commercialization model spanning proprietary product sales, strategic partnerships, contract manufacturing and technology licensing, as it advances through optimization, pilot-scale production and customer evaluation.
Dyadic (Nasdaq:DYAI) reported continued global collaborations validating its C1 protein production platform and expanding its commercial path.
C1-based monoclonal antibodies for RSV and malaria are fully funded by a $3.1 million Gates Foundation grant, while a $4.5 million CEPI/FBS collaboration has shown plasmid-to-purified-protein production in about 15 days. Dyadic targets an estimated $25 billion addressable biologics manufacturing opportunity through partner-funded programs, licensing, and commercial manufacturing.
Dyadic (Nasdaq: DYAI) announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. This strengthens its global IP portfolio and supports Dyadic’s C1 and Dapibus™ microbial production platforms.
Dyadic is also expanding business development in Japan through Intralink, with meetings planned in early July across multiple life science and industrial sectors.
Dyadic (Nasdaq: DYAI) reports rising interest in its C1 microbial protein platform amid Bundibugyo Ebola preparedness and broader commercialization. The platform has progressed from viral gene sequence to purified antigen or monoclonal antibody in about 15 days, which Dyadic views as important for outbreak response.
According to the company, C1 is being evaluated in three Ebola-related tracks with Scripps Research, CEPI-focused proposals, and an initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub. Dyadic also highlights commercial launches of C1- and Dapibus-produced proteins across biopharma, life sciences, food, nutrition and industrial markets.
Dyadic (NASDAQ: DYAI) and Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus linked to Hantavirus Pulmonary Syndrome. The work uses Dyadic’s fungal-based C1 platform for rapid, scalable biologic production to support future infectious disease preparedness.
The collaboration builds on prior Andes, Ebola and Marburg research, preclinical data showing C1-produced antibodies with comparable binding and neutralization to mammalian systems, and funded programs with the Gates Foundation, CEPI, FBS and EU initiatives.
Dyadic (NASDAQ: DYAI) reported Q1 2026 revenue of $1.11 million, up 182.3% year over year, with net loss narrowing to $1.95 million or $(0.05) per share. Cash and securities were $6.6 million on March 31, 2026.
The company highlighted commercial launches and agreements across life sciences, food and nutrition, and bio-industrial markets, including products such as recombinant albumin, DNase I, transferrin, alpha-lactalbumin and non-animal chymosin, plus progress in Gates Foundation and CEPI-supported biopharmaceutical programs.
Dyadic (Nasdaq: DYAI) will report Q1 2026 financial results and host a corporate update conference call on Wednesday, May 13, 2026 at 5:00 p.m. ET. The live dial-in and webcast details are provided below; an archived replay will be available within 24 hours on the company's Investor Relations website.
Dial-in numbers: Toll Free +1-877-407-9219 / +1-412-652-1274. Conference ID: 13759380. Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qVNgtGJ6. Submit Q&A questions in advance to jlavalley@dyadic.com.
Dyadic Applied BioSolutions (NASDAQ: DYAI) reported 2025 results and announced multiple commercial agreements and product launches. Key financials: cash ~$8.59M, total revenue $3.09M (2025 vs $3.50M 2024), and net loss $7.36M or $(0.23) per share.
Commercial progress includes the commercial launch of AlbuFree™ DX with Proliant, launch of RNase-free DNase I with Fermbox, an OEM distribution deal with IBT Bioservices, and a BRIG Bio agreement for recombinant alpha-lactalbumin.
Dyadic (NASDAQ: DYAI) announced an OEM distribution agreement with IBT Bioservices on March 16, 2026 to commercialize Dyadic-produced recombinant proteins for research-use-only applications. Initial products include recombinant DNase I and recombinant transferrin (human and bovine), leveraging IBT’s global sales channels to expand market access.
The collaboration complements Dyadic’s manufacturing and portfolio expansion, supports the company’s shift toward product-based revenues, and allows flexibility for future distribution, licensing of production strains, or partner-led manufacturing.
Dyadic (Nasdaq: DYAI) will report full year 2025 financial results and host a corporate update conference call on Wednesday, March 25, 2026 at 5:00 p.m. ET.
The live call will use dial-in numbers and a webcast; an archive will be available within 24 hours on the company's Investor Relations website. Investors may submit Q&A questions in advance by email.